Pembrolizumab: given beside what is tested

1,547 studies: usual care or a partner of the new treatment. Page 10 of 16. Open to participants first (520), then studies with results posted, then the rest; newest registration first within each.

Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant MelanomaActive, not recruitingNCT07428252Not applicable Report a problem
Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung CancerWithdrawnNCT07353957Phase 2 Report a problem
Pembrolizumab + MRGOO3 as Neoadjuvant in NPCActive, not recruitingNCT07267338Phase 2 Report a problem
Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and ImmunotherapyWithdrawnNCT07199413Phase 1 Report a problem
Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate CancerWithdrawnNCT07090369Phase 1 Report a problem
Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)WithdrawnNCT07073183Phase 1 Report a problem
A Study of LY4175408 in Participants With Advanced CancerActive, not recruitingNCT07046923Phase 1 Report a problem
PD-1 Inhibitor Combined With 125I Seed Implantation for Hepatocellular Carcinoma's Extrahepatic Metastasis: Efficacy and SafetyCompletedNCT06991907Not applicable Report a problem
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)Active, not recruitingNCT06961006Phase 2 Report a problem
Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )TerminatedNCT06939036Phase 1/2 Report a problem
A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid TumorsActive, not recruitingNCT06932952Phase 1 Report a problem
NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT06919666Phase 1/2 Report a problem
A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)CompletedNCT06894771Phase 1 Report a problem
A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid TumorsTerminatedNCT06877533Phase 1 Report a problem
Zoledronic Acid Combined With EC-T for Triple-Negative Breast CancerActive, not recruitingNCT06876636Not applicable Report a problem
A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)WithdrawnNCT06829199Phase 2 Report a problem
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab AloneActive, not recruitingNCT06806852Phase 1 Report a problem
Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaTerminatedNCT06790966Phase 3 Report a problem
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)Active, not recruitingNCT06788912Phase 2 Report a problem
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic MelanomaActive, not recruitingNCT06784648Phase 1/2 Report a problem
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid TumorsActive, not recruitingNCT06771622Phase 1/2 Report a problem
Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric AdenocarcinomaSuspendedNCT06728657Phase 2 Report a problem
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)Active, not recruitingNCT06726265Phase 3 Report a problem
A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell CarcinomaTerminatedNCT06716853Phase 1/2 Report a problem
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerActive, not recruitingNCT06711900Phase 3 Report a problem
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.TerminatedNCT06704724Phase 1 Report a problem
CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched RegimenActive, not recruitingNCT06699836Phase 2 Report a problem
A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 MutationTerminatedNCT06682806Phase 2 Report a problem
Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal CarcinomaCompletedNCT06676293Not applicable Report a problem
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic AlterationsActive, not recruitingNCT06644768Phase 1/2 Report a problem
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)Active, not recruitingNCT06635824Phase 3 Report a problem
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsActive, not recruitingNCT06607185Phase 1 Report a problem
Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1Active, not recruitingNCT06579196Phase 1/2 Report a problem
A Study of LY4050784 in Participants With Advanced or Metastatic Solid TumorsActive, not recruitingNCT06561685Phase 1 Report a problem
LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)TerminatedNCT06558799Phase 2 Report a problem
A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma PatientsActive, not recruitingNCT06540391Phase 1 Report a problem
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)Active, not recruitingNCT06525220Phase 3 Report a problem
A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal CancerWithdrawnNCT06513884Phase 2/3 Report a problem
A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic CancerWithdrawnNCT06498518Phase 2 Report a problem
A Phase 2 Study Using Aliya PEF Plus Pembro for SarcomaWithdrawnNCT06494787Phase 2 Report a problem
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)Active, not recruitingNCT06483334Phase 1/2 Report a problem
A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1)CompletedNCT06470763Phase 1/2 Report a problem
A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)CompletedNCT06460961Phase 1 Report a problem
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT06448312Phase 3 Report a problem
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.Active, not recruitingNCT06447662Phase 1 Report a problem
Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)TerminatedNCT06405230Phase 1/2 Report a problem
A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)WithdrawnNCT06395090Phase 1/2 Report a problem
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic CancerActive, not recruitingNCT06381154Phase 2 Report a problem
PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCCCompletedNCT06366451Early Phase 1 Report a problem
PSMA Therapy and Immunotherapy in Kidney CancerWithdrawnNCT06361810Phase 1/2 Report a problem
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBCTerminatedNCT06351332Phase 1 Report a problem
Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.Status unknownNCT06344715Phase 1 Report a problem
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).Active, not recruitingNCT06333951Phase 1 Report a problem
A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid TumorsActive, not recruitingNCT06328673Phase 1 Report a problem
Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural MesotheliomaActive, not recruitingNCT06318286Phase 2 Report a problem
Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell CarcinomaCompletedNCT06308913Early Phase 1 Report a problem
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).Active, not recruitingNCT06307431Phase 2 Report a problem
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)Active, not recruitingNCT06305767Phase 1/2 Report a problem
Trial of INI-4001 in Patients With Advanced Solid TumoursCompletedNCT06302426Phase 1 Report a problem
A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)TerminatedNCT06295809Phase 2/3 Report a problem
Efficacy and Safety of Combination Therapy With Bojungikki-tang and Pembrolizumab Monotherapy in Patients With Advanced Non-small Cell Lung CancerCompletedNCT06249854Phase 2 Report a problem
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLCActive, not recruitingNCT06246110Phase 2 Report a problem
TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCCCompletedNCT06236425Phase 1 Report a problem
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)Active, not recruitingNCT06225596Phase 2 Report a problem
Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)SuspendedNCT06219174Phase 1/2 Report a problem
BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid TumorsActive, not recruitingNCT06205706Phase 1/2 Report a problem
Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable MelanomaWithdrawnNCT06190249Phase 1 Report a problem
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic TumorsTerminatedNCT06188208Phase 1 Report a problem
A Study of ASP1012 in Adults With Solid TumorsTerminatedNCT06171178Phase 1 Report a problem
T Cells and Pembrolizumab for Recurrent and Newly Diagnosed GlioblastomaActive, not recruitingNCT06157541Phase 1/2 Report a problem
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid TumorsCompletedNCT06131398Phase 1 Report a problem
Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO TrialActive, not recruitingNCT06128863Phase 2 Report a problem
Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung CancerActive, not recruitingNCT06125197Phase 1 Report a problem
A Study of GC101 TIL in Advanced Melanoma (BZ)CompletedNCT06120712Phase 1/2 Report a problem
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.Active, not recruitingNCT06116136Phase 1/2 Report a problem
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal CancerActive, not recruitingNCT06109467Phase 2 Report a problem
Study of DF6215 in Patients With Advanced Solid TumorsCompletedNCT06108479Phase 1 Report a problem
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT06082167Phase 2/3 Report a problem
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)Active, not recruitingNCT06077760Phase 3 Report a problem
Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC ImmunotherapyActive, not recruitingNCT06074029Phase 1/2 Report a problem
A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid TumorsActive, not recruitingNCT06057038Phase 1 Report a problem
Study of ALE.C04 in Patients With Head and Neck CancerTerminatedNCT06054477Phase 1/2 Report a problem
Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)Active, not recruitingNCT06049212Phase 1 Report a problem
GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial CancerWithdrawnNCT06046274Phase 2 Report a problem
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)CompletedNCT06036836Phase 2 Report a problem
CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid TumorsTerminatedNCT06035744Phase 1 Report a problem
Pembrolizumab/Lenvatinib With and Without Healthy Donor FMT (hdFMT) in Relapsed/ Refractory (R/R) MelanomaWithdrawnNCT06030037Phase 2 Report a problem
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)TerminatedNCT06022757Phase 1/2 Report a problem
Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal CancerTerminatedNCT06006923Phase 2 Report a problem
GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract CancerTerminatedNCT05998447Phase 2 Report a problem
A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid TumorsTerminatedNCT05996445Phase 1 Report a problem
Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell CarcinomaActive, not recruitingNCT05980000Phase 2 Report a problem
Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).Active, not recruitingNCT05977907Phase 2 Report a problem
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid TumorsActive, not recruitingNCT05945823Phase 2 Report a problem
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)Active, not recruitingNCT05933577Phase 3 Report a problem
A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial CarcinomaActive, not recruitingNCT05929235Phase 1 Report a problem
Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial CarcinomaActive, not recruitingNCT05923190Phase 2 Report a problem
Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity CancerActive, not recruitingNCT05920798Phase 1/2 Report a problem
GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT05913388Phase 2 Report a problem
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2Active, not recruitingNCT05911295Phase 3 Report a problem

← Pembrolizumab